Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma

Oncotarget

Volumn 5, Issue 1, 2014, Pages 161-172

  Wolter, Jennifer K ^a,b   Wolter, Nikolaus E ^a   Blanch, Alvaro ^b   Partridge, Teresa ^b   Cheng, Lynn ^b   Morgenstern, Daniel A ^a,b   Podkowa, Monika ^b   Kaplan, David R ^a,b   Irwin, Meredith S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Beta adrenergic receptor; Neuroblastoma; p53; p73; Propranolol

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIRTECAN; MESSENGER RNA; METOPROLOL TARTRATE; PROPRANOLOL; PROTEIN P53; PROTEIN P73; BETA ADRENERGIC RECEPTOR; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; OVERALL SURVIVAL; TUMOR XENOGRAFT; ANIMAL; AUTONOMIC NERVOUS SYSTEM DISEASES; CELL GROWTH; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOUSE; NERVOUS SYSTEM NEOPLASMS; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; APOPTOSIS; AUTONOMIC NERVOUS SYSTEM DISEASES; CELL GROWTH PROCESSES; DNA-BINDING PROTEINS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NERVOUS SYSTEM NEOPLASMS; NEUROBLASTOMA; NUCLEAR PROTEINS; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893854541     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1083     Document Type: Article

References (64)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211
3. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DVS, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam GS. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 2011; 10: 188-195
4. Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, Fine N, Simpson CD, Sharmeen S, Rottapel R, Schimmer AD. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010; 115: 4824-4833
5. Yip KW, Mao X, Au PYB, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu F-F. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin Cancer Res 2006; 12: 5557-5569
6. Smith KM, Datti A, Fujitani M, Grinshtein N, Zhang L, Morozova O, Blakely KM, Rotenberg SA, Hansford LM, Miller FD, Yeger H, Irwin MS, Moffat J, Marra MA, Baruchel S, Wrana JL, Kaplan DR. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2010; 2: 371-384
7. Blatt J, Corey SJ. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discovery Today 2013; 18: 4-10
8. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J-B, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651
9. Bernabe DG, Tamae AC, Biasoli ÉR, Oliveira SHP. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain Behavior and Immunity 2011; 25: 574-583
10. Liu X, Wu WKK, Yu L, Sung JJY, Srivastava G, Zhang ST, Cho CH. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem 2008; 105: 53-60
11. Eldeeb BB, Hammond EM, Worthington DJ, Mann JR. Urinary catecholamines and their metabolites in management of neuroblastoma. Pediatr Hematol Oncol 1988; 5: 229-237
12. Hajighasemi F, Mirshafiey A. In vitro sensitivity of leukemia cells to propranolol. J Clin Med Res 2009; 1: 144-149
13. Zhang D, Ma Q-Y, Hu H-T, Zhang M. ß2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther 2010; 10: 19-29
14. Zhang D, Ma Q, Shen S, Hu H. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas 2009; 38: 94-100
15. Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G. The ß-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol Rep 2010; 24: 1669-1676
16. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. 2010; 1: 628-638
17. Wolter NE, Wolter JK, Enepekides DJ, Irwin MS. Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma. J Otolaryngol Head Neck Surg 2012; 41: 334-344
18. De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P. Treatment with ß-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011; 171: 779-781
19. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. Journal of Clinical Oncology 2011; 29: 2635-2644
20. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo A-M. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 2011; 29: 2645-2652
21. Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012; 127: 375-378
22. Pickoff AS, Zies L, Ferrer PL, Tamer D, Wolff G, Garcia O, Gelband H. High-dose propranolol therapy in the management of supraventricular tachycardia. The Journal of Pediatrics 1979; 94: 144-146
23. Love JN, Sikka N. Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med 2004; 26: 309-314
24. Huang X-Y, Wang H-C, Yuan Z, Huang J, Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via ß-adrenergic receptor-dependent activation of P38/MAPK pathway. Hepatogastroenterology 2012; 59: 889-893
25. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. JNCI Journal of the National Cancer Institute 2006; 98: 1193-1203
26. Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, Schleiermacher G, Delattre O, Janoueix-Lerosey I. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes Cancer 2008; 47: 819-834
27. Ohtaki M, Otani K, Hiyama K, Kamei N, Satoh K, Hiyama E. A robust method for estimating gene expression states using Affymetrix microarray probe level data. BMC Bioinformatics 2010; 11: 183
28. Lastowska M, Cotterill S, Pearson AD, Roberts P, McGuckin A, Lewis I, Bown N. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. European Journal of Cancer 1997; 33: 1627-1633
29. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483: 589-593
30. Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, Towers AJ, Williams B, Lam CM, Xiao K, Shenoy SK, Gregory SG, Ahn S, Duckett DR, Lefkowitz RJ. A stress response pathway regulates DNA damage through ß2-adrenoreceptors and ß-arrestin-1. Nature 2011; 477: 349-353
31. Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, Irwin MS. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 2007; 26: 1920-1931
32. Wolter J, Angelini P, Irwin M. p53 family: Therapeutic targets in neuroblastoma. Future Oncol 2010; 6: 429-444
33. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 403-410
34. Subbaramaiah K. Inhibition of Cyclooxygenase-2 Gene Expression by p53. Journal of Biological Chemistry 1999; 274: 10911-10915
35. Lau LMS, Wolter JK, Lau JTML, Cheng LS, Smith KM, Hansford LM, Zhang L, Baruchel S, Robinson F, Irwin MS. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 2009; 28: 2024-2033
36. Cushing SL, Boucek RJ, Manning SC, Sidbury R, Perkins JA. Initial Experience With a Multidisciplinary Strategy for Initiation of Propranolol Therapy for Infantile Hemangiomas. Otolaryngology -- Head and Neck Surgery 2010; 144: 78-84
37. Shang ZJ, Liu K, Liang DF. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 2009; 38: 371-376
38. Pérez Piñero C, Bruzzone A, Sarappa MG, Castillo LF, Lüthy IA. Involvement of a2- and ß2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol 2011; 166: 721-736
39. Chan C, Lin H-J, Lin J. Stress-associated hormone, norepinephrine, increases proliferation and IL-6 levels of human pancreatic duct epithelial cells and can be inhibited by the dietary agent, sulforaphane. int J Oncol 2008; 33: 415-419
40. Park PG, Merryman J, Orloff M, Schuller HM. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Research 1995; 55: 3504-3508
41. Weddle DL, Tithoff P, Williams M, Schuller HM. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 2001; 22: 473-479
42. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 2013; 24: 1312-1319
43. Lemeshow S, Sørensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser R. ß-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 2273-2279
44. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L, Linardopoulos S. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Molecular Cancer Therapeutics 2011; 10: 2115-2123
45. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15: 67-78
46. Blint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH. Induction of p57(KIP2) expression by p73beta. Proc Natl Acad Sci USA 2002; 99: 3529-3534
47. Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C, Tanaka T, Imai K, Nakamura Y, Tokino T. The p53 family member genes are involved in the Notch signal pathway. J Biol Chem 2002; 277: 719-724
48. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C. p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Research 2005; 65: 2186-2192
49. Farhang Ghahremani M, Goossens S, Haigh JJ. The p53 family and VEGF regulation: "It's complicated". Cell Cycle 2013; 12: 1331-1332
50. Bravo-Calderón DM, Oliveira DT, Marana AN, Nonogaki S, Carvalho AL, Kowalski LP. Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma. Cancer Biomark 2011; 10: 51-59
51. Pottier N, Paugh SW, Ding C, Pei D, Yang W, Das S, Cook EH, Pui C-H, Relling MV, Cheok MH, Evans WE. Promoter polymorphisms in the ß-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemia. Clin Pharmacol Ther 2010; 88: 854-861
52. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12: 419-431
53. Ji Y, Li K, Xiao X, Zheng S, Xu T, Chen S. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J Pediatr Surg 2012; 47: 2216-2223
54. Dey M, Brisson J, Davis G, Enever R, Pray K, Zaim B, Dvornik D. Relationship between plasma propranolol concentration and dose in young, healthy volunteers. Biopharm Drug Dispos 1986; 7: 103-111
55. Xie W, Xie H, Liu F, Li W, Dan J, Liu L, Dan L, Xiao X, Li J, Chen X. Propranolol induces apoptosis of human umbilical vein endothelial cells through down-regulation of CD147. Br J Dermatol 2012;
56. Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M. ß-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 2013;
57. Shakhar G, Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 1998; 160: 3251-3258
58. Potter DE, Schambelan M, Salvatierra O, Orloff S, Holliday MA. Treatment of high-renin hypertension with propranolol in children after renal transplantation. The Journal of Pediatrics 1977; 90: 307-311
59. Neil-Dwyer G, Bartlett J, McAinsh J, Cruickshank JM. Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol 1981; 11: 549-553
60. Morgenstern DA, Baruchel S, Irwin MS. Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy. J Pediatr Hematol Oncol 2013; inpress
61. Saulnier Sholler G. A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Future of clinical genomics in pediatric oncology 2012; 03: 602-612
62. Janeway KA, Place AE, Kieran MW, Harris MH. Future of clinical genomics in pediatric oncology. Journal of Clinical Oncology 2013; 31: 1893-1903
63. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115: 207-216
64. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.